Aktuellt
SENASTE
Redeye comments on Oncopeptides' Q1 report, which had few surprises in terms of financials. Commercial progress has been made with a successfully negotiated price and reimbursement in Spain, which will be an important market in reaching overall profitability.
LÄS MER
